Background: Cerebral cavernous malformation (CCM) is a rare disease associated with a latent risk of intracranial hemorrhage. However, due to limited evidence, the safety of recommending intravenous tissue plasminogen activators for patients with acute stroke and CCM remains uncertain.
Methods: Our study identified five patients with acute stroke and CCM treated between 2017 and 2023 across two hospitals.